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Abstract
Background. Althoughpancreastransplantation(PT)isthe
treatmentofchoiceinselecteddiabeticpatients,theInterna-
tionalPancreasTransplantRegistry(IPTR)hasreportedim-
portant differences in activity between USA and Europe. Of
all cases reported, 75% are from USA and only 23% from
Europe. Therefore, an analysis of PTactivity inselected Eu-
ropean countries (SEC) and USAwas performed.
Materials and methods. We compared national data re-
ports (2002–06) of deceased donors (DD) and deceased
solid organ transplantation (DSOT), with special attention
to PT activity from 13 SEC countries (375 million inhabi-
tants) and USA (298 million inhabitants).
Results. The number of PT performed in USA was 2-fold
higher than in SEC, with the annual rate >2.4 times higher
inUSA [5.08–4.64 versus1.61–1.91per million population
(p.m.p.)]. DD and other DSOT activity rates were only
slightly higher in USA. In SEC, important differences in
PT activity rate were found between countries in the same
year (0–6.21 p.m.p.) and in the same country between dif-
ferent years (6.21–2.47 p.m.p.), unrelated to DD or other
DSOT activity rate. PT activity rate increased in SEC from
1.61 to 1.91 p.m.p. but decreased in six countries. Thewait-
ing list for PTat the end of 2006 was almost 2-fold higher in
USA than in SEC.
Conclusions. Differences in PT activity rate between 13
SEC countries and USA were not related to DD or other
DSOTactivity. Different waiting list inclusion criteria or in-
cidence of diabetes complications may be considered in
more specific studies.
Keywords: deceased donors; diabetes mellitus; pancreas transplantation;
solid organ transplantation; transplant activity
Introduction
Despite improvement in insulin therapy, pancreas trans-
plantation (PT) is currently the only treatment that restores
normal glucose metabolism and substantially improves the
quality of life in type 1 diabetes mellitus (T1DM) patients
[1,2]. Depending on donor characteristics and the clinical
condition of the recipient, there are differences in both
graft and patient survival [3,4]. In diabetic patients with
end-stage renal disease (ESRD), simultaneous pancreas-
kidney transplantation (SPKT) offers lower patient mortal-
ity than patients on the waiting list or deceased donor (DD)
kidney transplant recipients [5–9]. The advantage in pa-
tient survival of pancreas after kidney (PAKT) or pancreas
transplantation alone (PTA) over conventional therapy re-
mains controversial [5,6].
According to the International Pancreas Transplant
Registry (IPTR), at 31 December 2004, >23 000 pancreas
transplants had been reported, with a higher proportion
performed in USA (n=17 132) than in non-USA
countries (n=5294) where 89% were performed in Eur-
ope [3]. Moreover, between 2000 and 2004, the annual
number of PT reported in USA remained constant at
~1400, while in non-USA countries, the number of re-
ported cases decreased from >450 to ~250 in the same
period [3]. The discrepancy in PT activity between USA
and Europe may be due, at least in part, to differences
in the reporting registry. While the IPTR has a relation
with the United Network for Organ Sharing (UNOS) of
USA and transplant activity report to UNOS is manda-
tory, such reports from non-USA countries are voluntary
[3]. However other factors, such us decease organ do-
nation, other deceased solid organ transplant (DSOT) ac-
tivity, waiting list inclusion criteria and prevalence of
T1DM or ESRD secondary to T1DM, may play a role
in the differences of reported PTworldwide when adjusted
to population.
The primary objective of the present study was to
compare the true incidence of pancreas transplant activ-
ity between USA and 13 selected European countries
(SEC) and secondly, to evaluate the relationship with de-
ceased organ donation and other DSOT activity during
the period between 2002 and 2006. Obviously, this could
help to optimize pancreas transplant policies around the
world.
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For the period 2002–06, we analysed databases from different national
transplant organizations (France, Italy, Spain, Switzerland and United
Kingdom) [10–14], other European countries included in organ exchange
organizations, such as Eurotransplant (Austria, Belgium, Germany and
The Netherlands) [15], Scandiatransplant (Denmark, Finland, Norway
and Sweden) [16], and the UNOS from USA [17]. In all cases, the annual
report included the period between 1 January and 31 December, except
for the United Kingdom which analysed the financial year (between 1
April and 31 March of the next year) [14]. For the purposes of this study,
the 13 European countries previously mentioned are defined as SEC.
Other European countries with >105 million inhabitants had some PT
activity, such as Bulgaria, Czech Republic, Croatia, Poland, Hungary,
Portugal, Ireland and Rumania [18,19], but we were unable to obtain
any data from their National Transplant Organizations. In order to ensure
the validity of the results from database reports, these were checked in-
dependently by the four authors (JMGP, DM, LPTand PG) and then com-
pared with the results published every year by the Council of Europe in
the Transplant Newsletter [19]. In most cases, there were no differences
or they were minimal and due to the inclusion of some islet cells trans-
plantation activity (see below); in any case, the data reports from the dif-
ferent transplant organizations were taken as accurate.
The number of DD, PT, deceased donor kidney transplantations
(DDKT), deceased donor liver transplantations (DDLT) and heart trans-
plantations (HT) for each year was obtained. As the pancreas is the organ
mostfrequentlytransplantedtogetherwithanotherorgan, twocategories of
PTwere considered according to the renal function of the recipient: SPKT
in patientswith ESRD and solitary PTin patientswithout current renal dis-
ease. Islet cell transplantation was not considered. Likewise, we recorded
the number of patients on the pancreas transplant waiting list at the end of
each year. As PT from living donors is only exceptionally performed; any
transplant activity involving living donorswas not included in the analysis.
In order to take into account demographic differences between
countries for comparative purposes, the total number of PT, DD and other
DSOT activity was calculated, and the rates were expressed as incidence
per million population (p.m.p.). The population of each European country
in the different years was obtained from the Statistical Office of the Eu-
ropean Communities (Eurostat) [20] and the USA population from the US
Census Bureau [21].
Results
The total number corresponding to DD, PTactivity and PT
active waiting list are shown in Table 1 together with de-
mographic changes in the different countries and years. In
USA, the total number of PT decreased from 1460 in 2002
to 1386 in 2006 (−5%) and the rate from 5.08 p.m.p. in
2002 to 4.64 in 2006 (−8.7%). By contrast, in SEC, the
total number increased from 591 in 2002 to 718 in 2006
(21.5%) as well as the rate from 1.61 p.m.p. in 2002 to
1.91 p.m.p. in 2006 (18.6%). This increment was mainly
due to increased PT activity rate in five countries (France,
Italy, The Netherlands, Spain and especially United King-
dom), which outweighed the decreases recorded in six oth-
er countries (Austria, Belgium, Germany, Norway, Sweden
and Switzerland). In two SEC (Denmark and Finland),
there was no reported PT activity during the period ana-
l y s e d( T a b l e1a n dF i g u r e1 ) .O n l yt w oS E C( A u s t r i a
and Belgium) showed a higher rate of PT activity than
USA for any of the 5 years analysed. Surprisingly, in Bel-
gium, this rate decreased from 6.21 p.m.p. in 2002 to 2.47
p.m.p. in 2006 (−60.2%). The PT rate was at least 2.4
Table 1. Population, total number of pancreas transplants, pancreas waiting list and DD in USA and 13 European countries
USA Europe
a Austria Belgium Denmark Finland France Germany Italy Netherlands Norway Spain Sweden Switzerland UK
Population
b
2002 287.67 366.73 8.07 10.31 5.37 5.19 61.40 82.44 56.99 16.10 4.52 40.96 8.91 7.25 59.22
2003 290.34 368.82 8.10 10.36 5.38 5.21 61.83 82.54 57.32 16.19 4.55 41.66 8.94 7.31 59.44
2004 293.03 371.05 8.14 10.40 5.40 5.22 62.25 82.53 57.89 16.26 4.58 42.34 8.98 7.36 59.70
2005 295.73 373.34 8.21 10.45 5.41 5.24 62.64 82.50 58.46 16.30 4.61 43.04 9.01 7.41 60.06
2006 298.44 375.29 8.27 10.51 5.43 5.26 63.00 82.44 58.75 16.33 4.64 43.76 9.05 7.46 60.39
Pancreas Tx
c
2002 1460 591 43 64 0 0 59 161 77 17 17 69 8 13 59
2003 1373 614 37 41 0 0 70 191 77 17 17 74 17 14 59
2004 1483 657 37 24 0 0 103 187 95 22 10 74 8 11 86
2005 1444 678 33 24 0 0 92 165 87 21 11 96 7 9 133
2006 1386 718 39 26 0 0 90 141 90 23 6 94 6 10 193
Pancreas WL
d
2002 2835 897 38 56 0 0 189 180 245 15 11 47 20 6 90
2003 2747 877 42 56 0 0 199 145 213 14 11 75 19 5 98
2004 2388 918 36 53 0 0 178 158 216 34 13 79 14 8 132
2005 2071 920 38 34 0 0 169 169 197 40 10 87 15 16 145
2006 1984 1009 32 30 0 0 169 190 222 40 10 73 15 21 207
DD
e
2002 6190 6422 195 223 73 89 1198 1001 1020 202 62 1409 98 75 777
2003 6457 6598 187 248 75 85 1119 1110 1042 223 87 1443 114 95 770
2004 7150 6898 181 220 64 109 1291 1052 1203 228 90 1495 123 91 751
2005 7593 7159 200 237 63 85 1371 1185 1197 217 76 1546 128 90 764
2006 8024 7340 201 273 62 109 1442 1227 1231 200 76 1509 137 80 793
a
All 13 countries.
b
Million inhabitants.
c
Tx=transplants.
d
WL=waiting list.
e
DD=deceased donors.
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analysed (Figure 1). In USA, the total number of SPKT
increased from 905 in 2002 to 924 in 2006 (2%) represent-
ing 62 and 66.5%, respectively, of all PT activity. In SEC,
the total number of SPKT increased from 457 in 2002 to
605 in 2006 (32.4%), representing 77 and 84.5%, respec-
tively, of all PT activity. Only Italy showed a similar per-
centage of SPKT than USA, while Austria and Belgium
showed a lower percentage than the SEC median (data
not shown).
In USA, although the number of patients on the active
waiting list for PT at the end of each year decreased from
2835 in 2002 to 1984 in 2006 (−30%) (Table 1), the num-
ber of candidates awaiting PT that remained inactive in-
creased from 753 in 2002 to 1970 in 2006 (162%) (data
not shown). The number of patients on the active waiting
list in SEC increased from 897 in 2002 to 1009 in 2006
(12.5%). In five SEC countries (Austria, Belgium, France,
Italy and Sweden), it decreased; in another five (Germany,
The Netherlands, Spain, Switzerland and United King-
Fig. 1. Pancreas transplant activity rate (incidence per million population) in USA and 13 European countries considered together (SEC) and
individually during the period 2002–06.
Fig. 2. DD activity rate (incidence per million population) in USA and 13 European countries considered together (SEC) and individually during the
period 2002–06.
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change. In Denmark and Finland, there were no patients
on the active waiting list during the period analysed (Ta-
ble 1). We found no data about inactive candidates on the
PT waiting list in SEC.
Deceased donation increased in USA from 6190 in 2002
to 8024 in 2006 (26%) and in SEC from 6422 in 2002 to
7340 in 2006 (14.3%) (Table 1). The DD rate was higher
in USA (21.52 p.m.p. in 2002 and 26.89 p.m.p. in 2006)
than in SEC (17.51 in 2002 and 19.56 in 2006), but the
differences were not as high as in PT activity, only 1.2–
1.38 times higher during the period analysed. Three SEC
countries (Austria, Belgium and Spain) showed similar or
higher DD activity rate than USA, while France, Finland
and Italy showed a higher activity rate than the SEC medi-
an (Figure 2).
From 2002 to 2006, the total number of DDKT in-
creased in both USA (from 8593 to 10 659; 24.8%) and
SEC (from 10 736 to 11 955; 11.3%). Accordingly, DDKT
activity rate was slightly higher in USA, but five SEC
(Austria, Belgium, Finland, France and Spain) showed
higher activity rate than USA (Figure 3).
Fig. 3. Deceased kidney transplant activity rate (incidence per million population) in USA and 13 European countries considered together (SEC) and
individually during the period 2002–06.
Fig. 4. Deceased liver transplant activity rate (incidence per million population) in USA and 13 European countries considered together (SEC) and
individually during the period 2002–06.
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4969 in 2002 to 6362 in 2006 (28%), whereas a lower
increase was observed in SEC (from 4757 in 2002 to 5536
in 2006; 16.4%). DDLT activity rate was higher in USA
(17.27–21.32 p.m.p.) than in SEC (12.97–14.75 p.m.p.) be-
tween 2002 and 2006, but the differences were not as high
as in PT (only 1.3–1.44 times higher). Only two SEC
countries (Belgium and Spain) showed a higher DDLT ac-
tivity rate than USA (Figure 4).
The total number of HT was similar between 2002 and
2006 in USA (2155–2192; 1.7%) and SEC (1970–2011;
2.1%), with a higher activity rate in USA. Nevertheless,
four SEC (Austria, Belgium, Norway and Spain) showed
a similar or higher HT activity rate than USA (Figure 5).
The percentage of pancreata recovered and transplanted
from DD was higher in USA (23.6% in 2002 and 17.3% in
2 0 0 6 )t h a ni nS E C( 9 . 2 %i n2 0 0 2a n d9 . 9 %i n2 0 0 6 ) ,b u t
overall, this percentage decreased in USAwith respect to
SEC.However,fiveSEC(Austria,Belgium,Germany,Nor-
way and Switzerland) showed an important decrease in this
percentage, while in four (France, The Netherlands, Spain
and specially United Kingdom), it increased (Figure 6).
Fig. 5. Heart transplant activity rate (incidence per million population) in USA and 13 European countries considered together (SEC) and individually
during the period 2002–06.
Fig. 6. Number of pancreata recovered and transplanted from every 100 DD in USA and 13 European countries considered together (SEC) and
individually during the period 2002–06.
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Several observations on this analysis may be made. Firstly,
a large number of PT performed in non-USA countries are
not reported to the IPTR. Secondly, in USA, the rate of PT
w a sm u c hh i g h e rt h a ni nS E C .T h i r d l y ,t h e r ew a sg r e a t
variability between SEC countries in PT activity not relat-
ed to the number of DD or other organ transplant activity.
Finally, despite the increase in the number of patients on
the PTwaiting list in some countries, a high percentage of
pancreata are not recovered from DD.
The latest report of the IPTR, published in 2005, esti-
mated that <10% of non-USA PTactivity was not captured
by the Registry, with <250 cases reported in 2004 [3].
However in that year, our analysis showed that, in the 13
SEC analysed, the total number of PT performed were 657
cases. Moreover, according to other sources [18,19], in
2004, >200 PT cases were performed in Australia, New
Zealand, Canada, Turkey, Argentina, Uruguay, Republic
of Korea, Japan, Saudi Arabia and other European
countries (Czech Republic, Poland, Bulgaria, Hungary,
Portugal, Ireland and Romania). Additionally, in Brazil,
with no data for 2004, a total of 173 cases were reported
in 2006 to the Global Observatory on Donation and Trans-
plantation [18]. According to these data, recent PT activity
from non-USA countries may be higher than 1000 cases
per year, with no >30% being reported to the IPTR. Man-
datory reporting of all PT activity from national registries
to the IPTR is needed to allow worldwide comparisons.
We found important differences between countries in PT
activity rate not related to DD or other DSOTactivity. This
conclusion is sustained for different reasons. Although in
USA, the DD and other DSOT activity rates were higher
than in SEC, the differences were much higher in PT.
Moreover, while DD and other DSOT activity rate in-
creased in most countries, PT activity showed important
variability regardless of the evolution in DD or other trans-
plant activity. Furthermore, the differences observed be-
tween countries in the same year and in the same country
in different years did not show a similar evolution in DD
and other DSOTactivity rate. Another important difference
between USA and SEC is the higher percentage of SPKT
in SEC due to a lower proportion of solitary PT performed
in most SEC. It is plausible that in USA, with a higher
living donor kidney transplantation rate than SEC [19],
the high percentage of PAKT in which the kidney came
from a living donor (>60%) [3] may help to explain this
difference.
Another aspect highlighted by this analysis is the evolu-
tion of the PT waiting list. It decreased in USA and in-
creased in SEC despite the inverse evolution in PT
activity. The waiting list increase in SEC was mainly due
to the increment of candidates for PT in The Netherlands,
Spain and especially United Kingdom; however, these
countries together with France and Italy are the ones that
contribute to the overall increase in PT activity in SEC.
Paradoxically, the number of candidates on the active wait-
ing list at the end of 2006 was almost 2-fold higher in USA
with a lower population than in SEC. However, this may be
due to different criteria for registration on the waiting list
(older candidates) and different allocation policies as has
been observed in USA [22,23]. In addition, the gap be-
tween the demand (number of candidates on the active
waiting list) and the number of PT performed is higher
in USA and again, important differences were found be-
tween countries. It increased in Belgium, Germany, The
Netherlands, Norway and Switzerland but dropped in
USA, Austria, France, Italy, Sweden and United Kingdom.
This gap has been ‘negative’ (the number of PT performed
per year was higher than the number of waiting list candi-
dates at the end of the year), only occasionally in Austria,
Belgium, Germany, The Netherlands and more frequently
in Norway, Spain and Switzerland. In general, a very large
gap may indicate the need for greater PT activity.
Pancreas underutilization is another important challenge
and has been considered an important issue in USA
[22,24]. When comparing practises in SEC, we found var-
iable proportions of DD from whom pancreata were recov-
ered and transplanted. This proportion shows important
changes between countries and years, varying from <5 to
>25%. This may reflect the increased number of older do-
nors, although the lack of experience in some recovery
teams has been also considered [22,25]. PT activity actu-
ally decreased during the period analysed in most
countries and only increased in France, The Netherlands,
Spain and especially in the United Kingdom. It may also
be speculated that the option of maintaining the patient
with insulin therapy plays a role in pancreas underutiliza-
tion and most transplant teams only accept ideal organs
[25]. In this respect, studies from USA showed that the
non-recovery rate and the discard rate among recovered
pancreata increased in recent years [24,25]. Taking into ac-
count these data, important efforts must be made to improve
the underutilization of pancreata from DD, especially in
those countries with a long waiting list.
Other reasons could account for the differences ob-
served in PT activity rate between countries. A higher
prevalence of T1DM in USA than in Europe is one possi-
bility. However, according to the International Diabetes
Federation and the Diabetes Mondiale Project Group, the
incidence of T1DM in children (0–14 age range) is higher
in Europe than in North-America, with a very high inci-
dence (>20/100 000 per year) observed in Finland, Norway,
Sweden and United Kingdom [26,27]. More important than
the incidence of T1DM in children is, in this case, the in-
cidence of ESRD, at any age, secondary to T1DM. How-
ever, we found a very limited number of studies analysing
this issue in recent scientific literature [28–31]. This inci-
dence varies in Europe in 1999–2000, between 16.3 cases
p.m.p. in Denmark, ~13 cases p.m.p. in Finland, Sweden
and United Kingdom (Scotland), 8.3 cases p.m.p. in Aus-
tria, ~6 cases p.m.p. in Spain (Catalonia), Norway and The
Netherlands and 3.8 cases p.m.p. in Belgium (French-
speaking) [28–30]. Although this incidence has increased
in most countries with respect to the period 1991–92, it
decreased in Austria and especially in Belgium [28], and
in more recent years, it stabilized in Denmark [29] and de-
creased in The Netherlands [30]. This may be a reason for
the decrease in PT activity in some countries. On the other
hand, according to reports of the United States Renal Data
System, it can be calculated that the incidence of ESRD
secondary to T1DM decreased in USA from ~16 cases
Pancreas transplantation: differences in activity between Europe and United States 957p.m.p. in the period 1997–2001 to 13 cases p.m.p. in the
period 2002–06 [32,33]. The higher incidence of ESRD
secondary to T1DM in USA compared with SEC with a
lower incidence of T1DM may be due to an increased risk
of this complication among ethnic minorities (blacks and
Hispanics) in USA [34,35], although the role of disparities
in access to health care (universal in Europe and mostly
private in USA), especially for chronic disease such as
T1DM, requiring prolonged and regular treatment, should
also be considered [35].
Other potential explanations for the observed discrepan-
cies in PT may include different insurance reimbursement
policies and attitudes regarding the indication for PT, as
reflected by the different statements issued by scientific so-
cieties [36–39]. However, these factors may play a minor
role because PT is covered by the different national health
systems or private insurance in most SEC or by Medicare in
USA (except for PTA in USAwhich has only been covered
since April 2006) [22]. Moreover, similar specific recom-
mendations for PT in diabetic patients have been published
by the American Diabetes Association, the National Kid-
ney Foundation and the American Society of Transplanta-
tion [36–38] as well as the European Renal Association and
the European Society for Transplantation [39].
Finally, it is plausible that the clinical criteria for inclu-
sion on a PT waiting list vary between countries and even
between different teams in the same country, as previously
reported for SPKT in The Netherlands [7]. As an example,
SPKT is not indicated for ESRD diabetic patients in
countries with a high incidence of this complication (Den-
mark and Finland), where kidney transplant alone (KTA)
with more intensive treatment is the therapeutic option
used with improved results in patient survival in recent
years [16,40]. In addition, in USA, ~7% of all SPKT are
performed in type 2 diabetic patients [3], while there are
no comparable data from SEC. Although in a single-centre
study from Spain, this percentage was similar (5.2%) [41],
specific studies in the different SEC are needed in order to
determine whether there are differences in this attitude.
The development of PT has been historically limited by
the lack of randomized, controlled trials and relatively
poor survival but currently, surgical and immunosuppres-
sive advances have improved the results [42]. Although
KTA is clearly associated with a significant increase in life
expectancy when compared with diabetic patients remain-
ing on the waiting list [43], there is controversy as to
whether adding a pancreas contributes independently to
patient survival. While large population multi-centre and
single-centre studies comparing SPKT versus KTA have
found longer patient survival for SPKT recipients [7], reg-
istry-based analysis showed contradictory results [9,44–
46], probably limited to the information available in the
database from registries. In addition, the clear and signif-
icantly lower mortality risk, after the 3 months post-trans-
plantation period, in SPKT as compared with patients who
remained on the waiting list [5,6,9], is less evident for
PAKTand PTA [5,6]. These discrepancies may be a reason
for the differences in prevailing attitudes in the medical
community worldwide. A future survey of practitioners
in Europe and perhaps in USAwill better delineate the cur-
rent position regarding the utility of PT. Although a decade
ago, SPKTwas considered as optimal and the treatment of
choice for juvenile diabetic patients with ESRD for an in-
creasing number of centres in Europe [47], currently this
approach remains uncommon and even inexistent in some
European countries. Due to the high mortality, while on
dialysis, of this population [9,43], a debate is needed about
the reasons of disparities in PT activity in Europe.
In conclusion, PTactivity rate and activewaiting list can-
didates were higher in USA than in SEC countries. The dif-
ferences were not related to deceased donation or other
deceased transplant activity and are likely to be multifac-
torial. Future analyses are needed to determine whether
these results are due to differences in clinical indication
for PT, higher incidence of diabetic nephropathy second-
ary to T1DM or other unknown reasons.
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